Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0518 in ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07912268Phase 1Not yet recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0518 in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity, Adverse event Rate up to 24 months and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SIM0518
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07912268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912268.